This study aimed to determine if the neoadjuvant (NAT) KEYNOTE-522 regimen was associated with higher rates of pathologic complete response (pCR), corresponding to higher rates of breast conservation therapy (BCT) in early-stage triple-negative breast cancer (TNBC) patients.Stage II鈥揑II TNBC ...
2、Gianni L, et al. Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. ESMO Congress 2023, LBA19 3、Loi S, et al...
Additional prospective study with larger sample size is needed to understand whether all patients benefit from completing the Keynote 522 regimen.All RegimensChemo RegimensPembrolizumab%, Number of Patients (NoP) with Complications12.26% (N=13)54.72% (N=58)16.98% (N=18)NoP Completed Full Dose ...
Here we report the case of a patient diagnosed with clearly demarcated, pathologically heterogenous triple negative breast cancer (TNBC) and HER2+ breast cancer that was treated with a hybrid chemoimmunotherapy regimen combining elements of Keynote-522 and a standard HER2-directed neoadjuvant regimen,...